Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:alternativeName |
gptkb:erenumab
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
N02CD03
|
| gptkbp:brand |
gptkb:Aimovig
|
| gptkbp:CASNumber |
1334312-36-6
|
| gptkbp:developedBy |
gptkb:Amgen
gptkb:Novartis |
| gptkbp:form |
pre-filled syringe
auto-injector |
| https://www.w3.org/2000/01/rdf-schema#label |
AMG 334
|
| gptkbp:indication |
migraine prevention
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
human monoclonal antibody
|
| gptkbp:mechanismOfAction |
CGRP receptor antagonist
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
constipation
hypertension injection site reaction muscle spasm |
| gptkbp:target |
calcitonin gene-related peptide receptor
|
| gptkbp:UNII |
8Z6J2R58S3
|
| gptkbp:bfsParent |
gptkb:Arteaus_Therapeutics
|
| gptkbp:bfsLayer |
8
|